These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 10620464)
1. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Nagourney RA Gynecol Oncol; 2000 Jan; 76(1):143. PubMed ID: 10620464 [No Abstract] [Full Text] [Related]
2. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793 [TBL] [Abstract][Full Text] [Related]
3. Correlation between in vitro drug response in the EDR assay and response to primary paclitaxel and cisplatin. DiSaia PJ Gynecol Oncol; 1999 Jul; 74(1):148-9; author reply 149-50. PubMed ID: 10385571 [No Abstract] [Full Text] [Related]
4. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
5. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121 [TBL] [Abstract][Full Text] [Related]
6. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer]. Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005 [TBL] [Abstract][Full Text] [Related]
7. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma]. Zhao XD; Zhang Q; Zhang Y Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882 [TBL] [Abstract][Full Text] [Related]
8. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475 [TBL] [Abstract][Full Text] [Related]
10. [Efficacy and toxicity of a taxotere/cisplatin combination in first line chemotherapy in patients with disseminated ovarian cancer]. Gorbunova VA; Khokhlova SV; Besova NS; Orel NF; Kuznetsov VV; Bliumenberg AG; Smirnova NB; Chekalova MA; Sinitsyna ME; Poddubnyĭ BK Vopr Onkol; 2001; 47(5):1-6. PubMed ID: 11799946 [No Abstract] [Full Text] [Related]
11. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A; J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330 [TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel. Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790 [TBL] [Abstract][Full Text] [Related]
13. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer. Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821 [TBL] [Abstract][Full Text] [Related]
14. [Pharmacotherapy in ovarian carcinoma]. Pfisterer J; Du Bois A MMW Fortschr Med; 2005 Oct; 147(43):34-6. PubMed ID: 16302419 [TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal therapy of ovarian cancer. Markman M Semin Oncol; 1998 Jun; 25(3):356-60. PubMed ID: 9633848 [TBL] [Abstract][Full Text] [Related]
16. [Ovarian cancer treatment from the standpoint of the gynecologic oncologist]. Sugiyama T; Yoshizaki A; Hatayama S Gan To Kagaku Ryoho; 2007 Jul; 34(7):1011-6. PubMed ID: 17637537 [TBL] [Abstract][Full Text] [Related]
18. Cisplatin-paclitaxel-cyclophosphamide with G-CSF in primary advanced epithelial ovarian cancer. Fanning J; Colgrove M; Phibbs G Gynecol Oncol; 2000 Oct; 79(1):97-100. PubMed ID: 11006039 [TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look. Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026 [TBL] [Abstract][Full Text] [Related]